Cancer, chitosan nanoparticles and catalytic nucleic acids

被引:56
作者
Tan, Mei Lin [1 ,2 ]
Choon, Peter F. M. [1 ,2 ]
Dass, Crispin R. [1 ,2 ,3 ]
机构
[1] Univ Melbourne, St Vincents Hosp Melbourne, Dept Orthopaed, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia
[3] Peter MacCallum Canc Inst, Bone & Soft Tissue Sarcoma Serv, Melbourne, Vic 3000, Australia
关键词
cancer; chitosan; drug delivery systems; gene therapy; nanoparticles; SOLID TUMOR-GROWTH; IN-VITRO; GOLD NANOPARTICLES; GENE-THERAPY; C-JUN; MOLECULAR-WEIGHT; HEPATOCELLULAR-CARCINOMA; OLIGONUCLEOTIDE DELIVERY; CELL-PROLIFERATION; DNA ENZYMES;
D O I
10.1211/jpp/61.01.0002
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Objectives The aim of this review was to examine gene therapy involving DNAzyme and siRNA encapsulation into chitosan nanoparticles, discussing the Current and future status of this drug delivery system in enhancing drug delivery and cancer therapy. Key findings Cancer is a disease state in which the cells in our body undergo Mutations at the genetic level and are transformed, acquiring the ability to replicate limitlessly. Conventional cancer treatment involves the use of surgery and cytotoxic chemotherapy and/or radiotherapy, which have the potential of harming normal, otherwise healthy, nonneoplastic cells. Newer forms of therapy such as immunotherapy and gene therapy have shown initial promise, but still require better ways to limit exposure to cancerous lesions ill the body. As a result drug delivery systems have been developed in attempts to deliver therapeutics specifically to the target lesion site. One recent drug delivery system has revolved around the use of chitosan nanoparticle technology, where therapeutics are encapsulated into nanoparticles and targeted to tumours. Summary Though few, attempts at encapsulating therapeutics Such as deoxyribozymes and small or short interfering RNA have been optimistic and encouraging.
引用
收藏
页码:3 / 12
页数:10
相关论文
共 111 条
[1]
[Anonymous], CANC ITS MANAGEMENT
[2]
AVELLA M, 1998, CHEMOPTERAPIA, V7, P133
[3]
Control of tumour vascular permeability [J].
Baban, DF ;
Seymour, LW .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 34 (01) :109-119
[4]
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian sarcoma group/Scandinavian sarcoma group pilot study [J].
Bacci, G ;
Ferrari, S ;
Longhi, A ;
Picci, P ;
Mercuri, M ;
Alvegard, TA ;
Saeter, G ;
Donati, D ;
Manfrini, M ;
Lari, S ;
Briccoli, A ;
Forni, C .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (02) :198-206
[5]
Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles [J].
Banerjee, T ;
Mitra, S ;
Singh, AK ;
Sharma, RK ;
Maitra, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 243 (1-2) :93-105
[6]
Gene silencing nucleic acids designed by scanning arrays: Anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system [J].
Beale, G ;
Hollins, AJ ;
Benboubetra, M ;
Sohail, M ;
Fox, SP ;
Benter, I ;
Akhtar, S .
JOURNAL OF DRUG TARGETING, 2003, 11 (07) :449-456
[7]
Chitosan and lactic acid-grafted chitosan nanoparticles as carriers for prolonged drug delivery [J].
Bhattarai, Narayan ;
Ramay, Hassna R. ;
Chou, Shinn-Huey ;
Zhang, Miqin .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2006, 1 (02) :181-187
[8]
Brothers in arms - DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies [J].
Bhindi, Ravinay ;
Fahmy, Roger G. ;
Lowe, Harry C. ;
Chesterman, Colin N. ;
Dass, Crispin R. ;
Cairns, Murray J. ;
Saravolac, Edward G. ;
Sun, Lun-Quan ;
Khachigian, Levon M. .
AMERICAN JOURNAL OF PATHOLOGY, 2007, 171 (04) :1079-1088
[9]
Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin [J].
Bhumkar, Devika R. ;
Joshi, Hrushikesh M. ;
Sastry, Murali ;
Pokharkar, Varsha B. .
PHARMACEUTICAL RESEARCH, 2007, 24 (08) :1415-1426